Biogen Reports Earnings Exceeding Estimates by $1.27, Revenue Surpasses Expectations

Biogen reported a second-quarter earnings per share (EPS) of $5.28, surpassing the analyst estimate of $4.01 by $1.27. The company’s revenue for the quarter reached $2.47 billion, compared to the consensus estimate of $2.39 billion.

### Guidance
Biogen has projected an EPS for fiscal year 2024 in the range of $15.75 to $16.25, which is slightly above the analyst consensus of $15.58.

Currently, Biogen’s stock price is at $213.20. Over the past three months, the stock has declined by 1.98%, and it has seen a drop of 21.49% over the past year. In the last 90 days, Biogen experienced nine positive EPS revisions alongside six negative ones.

According to recent evaluations, Biogen’s financial health has been deemed “good performance.”

Stay informed about upcoming earnings reports by keeping an eye on the earnings calendar.